Genmab

The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Yahoo/Benzinga
Merck
relebactam
TapImmune
earnings
JNJ
Seattle Genetics
Abbott Labs
Intuitive Surgical
Mirum Pharmaceuticals
Fulcrum Therapeutics
Genmab
Flag link:
Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap
Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap
Endpoints
Genmab
IPOs
NASDAQ
Flag link:
J&J bags $150M option on Genmab's Darzalex successor
J&J bags $150M option on Genmab's Darzalex successor
Fierce Biotech
Genmab
JNJ
Darzalex
Multiple Myeloma
drug development
Flag link:
Genmab files for $500M IPO to fund multi-front cancer R&D push
Genmab files for $500M IPO to fund multi-front cancer R&D push
Fierce Biotech
Genmab
IPOs
antibody-drug conjugate
cervical cancer
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
daratumumab
patents
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys
Janssen
Genmab
patent lawsuits
patents
Darazalex
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
patents
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys
Janssen
Genmab
Flag link:
Genmab's blockbuster Darzalex surpasses $2B in sales
Genmab's blockbuster Darzalex surpasses $2B in sales
BioCentury
Genmab
Multiple Myeloma
Darzalex
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Flag link:
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Flag link:
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:
Danish biotech Genmab hit by ending of trial using key cancer drug
Danish biotech Genmab hit by ending of trial using key cancer drug
Reuters
Genmab
JNJ
Janssen
Darzalex
Flag link:
Genmab hits roadblock in non-Hodgkin lymphoma
Genmab hits roadblock in non-Hodgkin lymphoma
Biopharma Dive
Genmab
non-Hodgkin's lymphoma
Arzerra
clinical trials
Flag link:
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Fierce Pharma
Novartis
Arzerra
Genmab
CLL
chronic lymphocytic leukemia
Flag link:
Genmab and J&J 'love' partnership as some ponder takeover
Genmab and J&J 'love' partnership as some ponder takeover
Yahoo/Reuters
Genmab
JNJ
M&A
Darzalex
Flag link:
Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort
Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort
Endpoints
Seattle Genetics
Genmab
antibody-drug conjugate
tisotumab vedotin
Flag link:
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Flag link:
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Motley Fool
JNJ
devices
baby boomers
specialty medicines
M&A
Genmab
Imbruvica
Flag link:

Pages